The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy.
Weihua CaoMing-Hui LiLu ZhangYao LuShuling WuGe ShenMin ChangRuyu LiuYuanjiao GaoHongxiao HaoLeiping HuWei YiCalvin Qian PanYao XiePublished in: BioMed research international (2021)
In CHB patients, PEG-IFN-α treatment significantly enhanced NK cell frequency and function when compared to entacavir. Positive treatment responses to either interferon or entecavir were associated with NK cell function improvement. This trial is registered with clinical trial registration no. NCT03208998.
Keyphrases
- clinical trial
- nk cells
- end stage renal disease
- dendritic cells
- natural killer cells
- chronic kidney disease
- newly diagnosed
- study protocol
- phase ii
- peritoneal dialysis
- immune response
- hepatitis b virus
- randomized controlled trial
- open label
- mesenchymal stem cells
- replacement therapy
- cell therapy
- chemotherapy induced